Monoclonal antibody 8H9 I-124 - Y-mAbs Therapeutics

Drug Profile

Monoclonal antibody 8H9 I-124 - Y-mAbs Therapeutics

Alternative Names: 124I-8H9; 124I-8H9 (B7-H3)

Latest Information Update: 09 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD antigen modulators; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma

Most Recent Events

  • 02 Jun 2017 Safety and Pharmacokinetics data from a phase I trial in Glioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 18 Nov 2016 The US FDA grants Y-mAbs Therapeutics a rare pediatric disease designation for 8H9I-124 for the treatment of diffuse intrinsic pontine glioma
  • 09 Sep 2016 Phase-I/II clinical trials in Glioma in USA (Infusion) (Y-mAbs Therapeutics pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top